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Background: Recent advances have shown that histology and genetic biomarkers are important in patient
selection, which have led to significantly better outcomes for lung cancer patients. However, most new treatments
only apply to adenocarcinoma or non-squamous, and in squamous carcinoma there is little breakthrough. In a
phase III trial nab-paclitaxel plus carboplatin showed superior response rate over paclitaxel and carboplatin. In
subgroup analysis the squamous histology appeared to be a predictive factor to nab-paclitaxel treatment.
Methods/Design: This is an open-label, randomized, active controlled phase II trial. A total of 120 untreated
advanced squamous lung cancer patients are randomized at a 1:1 ratio to receive nab-paclitaxel (135 mg/m2, d1, 8, q3w)
plus carboplatin (AUC 5, d1, q3w) or gemcitabine (1,250 mg/m2, d1, 8, q3w) and carboplatin (AUC 5, d1, q3w). The
primary endpoint is objective response rate and the second endpoints are progression free survival, overall survival,
safety and biomarkers associated with nab-paclitaxel. The treatment will continue up to six cycles or intolerable toxicity.
Discussion: This ongoing trial will be the first prospective randomized trial to explore the efficacy of nab-paclitaxel as
the first-line treatment specifically in squamous carcinoma of lung.
Study number: CTONG1002
Trial Registration: Clinicaltrials.gov reference: NCT01236716
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For both men and women, lung cancer is the leading
cause of death and non-small cell lung cancer (NSCLC)
represents more than 80% of all lung cancer cases [1].
Compared with best supportive care, platinum-based
doublet chemotherapy not only prolongs the survival, but
also improves symptom control and the quality of life. It
has been the standard of care for advanced NSCLC
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efficacy in the first line setting [3].
Traditionally, the choice of chemotherapy is based
on performance status, age, etc, and histology has not
influenced the treatment options. Recent years, personalized
treatment has developed rapidly with the emerging of new
chemotherapy agents and targeted therapies. Pemetrexed
has favorable efficacy and safety profiles in non-squamous
NSCLC but not in squamous population [4]. The benefit of
bevacizumab is also limited to the non-squamous subtypes
[5]. Moreover, most targeted drugs need molecular markers
to distinguish patients who would likely to gain survival
advantage from treatment, such as epidermal growth
factor receptor (EGFR) mutation for EGFR tyrosine kinase
inhibitors (TKIs) [6,7], EGFR amplification for cetuximabd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for ALK inhibitor crizotinib [9]. Molecular-targeted drugs
have the advantages of prominent therapeutic efficacy and
moderate adverse reactions, prolonging patients’ survival
time and improving the quality of life at the same
time. EGFR-TKIs such as erlotinib and gefitinib have been
recommended as the first -line treatment in EGFR
mutation patients by clinical practice guidelines [2].
Despite all the progress in adenocarcinoma and
biomarker positive patients, the treatment breakthroughs
for squamous histology are few. Although the EGFR
mutated squamous lung cancer patients can be treated with
EGFR-TKIs as well, the mutation rate in this population is
much lower than that in the non-squamous subtypes
(around 10% in Caucasian adenocarcinoma patients, 30%
in Asian adenocarcinoma patients, but only around 3% in
squamous patients [10]). Thus major part of squamous
patients remains on platinum-based doublet with an
average objective response rate (ORR) around 20%
and overall survival (OS) no longer than 12 months.
Nab-paclitaxel (Abraxane) is a nano-technology devel-
oped albumin bound paclitaxel. With the natural affinity
of albumin to tumor cells, it enables paclitaxel to be con-
centrated in cancer lesion to exert bigger anti-neoplastic
effect. In a phase III trial of Abraxane plus carboplatin
versus solvent-based paclitaxel [11], Abraxane arm shows
significantly higher ORR than the solvent-based paclitaxel
arm (33% vs 25%, p = 0.005) and equivalent progression
free survival (PFS) and OS. The ORR benefit is especially
bigger in squamous subtype (41% vs 24%, p < 0.001) and
the OS beneficial trend is bigger in this group too.
With these promising findings of subtype analysis in
the phase III trial, this trial is designed to prospectively
explore the efficacy of Abraxane specifically in the squa-
mous population by a head to head comparison to current
standard of care.
Methods/Design
This study is a multicenter, randomized, active controlled,
open label phase II clinical trial. The objective is to study
the efficacy and safety of nab-paclitaxel and carboplatin
compared with gemcitabine and carboplatin as first-line
therapy in advanced squamous cell carcinoma of lung.
All patients in this study have locally advanced or
metastatic squamous cell carcinoma of lung which
has been histologically confirmed. The inclusion and
exclusion criteria are summarized in Table 1. This study
was approved by the ethics committees of Guangdong
General Hospital, Fujian Province Cancer Hospital,
Heilongjiang Province Cancer Hospital, Nanjing General
Hospital and Jilin Province Cancer Hospital respectively.
Recruitment for this study is currently ongoing in 5 sites
in China. Written informed consent must be provided by
all patients before any trial-related procedures are carriedout. 120 patients are randomly assigned to treatment
group A: receiving nab-paclitaxel 135 mg/m2, d1, 8 and
carboplatin AUC 5, d1 every three weeks; or group B:
receiving gemcitabine 1,250 mg/m2, plus carboplatin AUC
5, d1 every three weeks. Both group A and B receive up to
six cycles of chemotherapy.
Study objectives
The primary objective of this study is to compare the
ORR of Abraxane plus carboplatin to gemcitabine plus
carboplatin. Secondary objectives include PFS, OS, safety
and biomarker parameters. Exploratory endpoints include
expression of secreted protein acid rich in cysteine (SPARC)
and caveolin-1 in NSCLC tissue and their predictive value
in PFS and OS. Tumor samples will be collected from all
randomized patients and tested in the central lab of
Guangdong Lung Cancer Institute, Guangdong Academy
of Medical Sciences.
Statistics
The sample size calculation assumes that in advanced
squamous lung cancer, Abraxane + carboplatin has an
ORR of 40% [11] while gemcitabine + carboplatin has an
ORR of 19% [3]. With inequality test using ratios of two
independent proportions, the sample size is 120 patients
in total, which will be randomly assigned at a 1:1 ratio
between two treatment arms (60 in each). This sample
size will provide 80% power with two-sided type I error
of 0.05 to reject the primary efficacy null hypothesis that
Abraxane + carboplatin/gemcitabine + carboplatin hazard
ratio for ORR is equal to 1.0.
The primary objective will be analyzed by chi-square
test. Secondary endpoints of PFS and OS will be evaluated
by Kaplan-Meier method with a 95% confidence interval.
The log-rank method will be used to compare the difference
between the survival curves of two arms. Multifactorial Cox
regression analysis will be used to determine the prognostic
factors of the survivals including PFS and OS.
Ethical considerations
Prior to initiation of the study, each of the participating
sites must obtain local or central ethics committee
approval from the appropriate body. All research will
conform to the Declaration of Helsinki, as well as local
legal and ethical requirements.
Discussion
Previous researches have shown comparable efficacy and
good safety profile of Abraxane-based chemotherapy in
the first-line treatment of advanced NSCLC, compared to
other standard platinum-based doublets. In a phase III
trial, the ORR of Abraxane plus carboplatin is signifi-
cantly higher than solvent-based paclitaxel and the
survival time is equivalent in two groups [11]. The most
Table 1 Inclusion and exclusion criteria
Inclusion criteria • Previously untreated, histologically documented stage IIIB to stage IV or stage IIIA that is not
amenable to regional therapy (7th Edition of TNM Staging Criteria) squamous cell carcinoma of
lung. Previously untreated, histologically documented squamous cell carcinoma of lung with
stage IV or locally advanced disease that is not amenable to radical regional therapy
(7th Edition of TNM Staging Criteria).
• At least one measurable tumor lesion as defined by RECIST criteria.
• 18 to 85 years of age.
• ECOG performance status 0-1.
• Patients have no previously malignant tumors or history except cured cervical carcinoma in situ,
basal cell carcinoma or superficial bladder cancer (Ta, Tis or T1).
• Patients should not have been treated with chemotherapy such as gemcitabine, platinum and
taxane. But patients who have received chemotherapy for neoadjuvant or adjuvant treatment at
least 12 months before the study treatment are eligible.
• Patients’ blood test must meet the following requirements:
o ANC ≥ 1.5 x 109/L
o Platelets ≥ 100 x 109/L
o Hb ≥ 90 g/L (9 g/dL)
• Patients’ clinical biochemistry examination must meet the following requirements:
o ALT and AST ≤ 2.5 x upper limit of normal (ULN) without liver metastasis, ALT and AST ≤ 5 x ULN
with liver metastases
o Serum creatinine ≤ 1.5 x ULN
o Total bilirubin ≤ 1.5 x ULN
• Urine pregnancy test is negative for women, within 14 days before study treatment.
• Estimated life expectancy of at least 3 months.
• Patients will comply with the clinical trial protocol.
• Patients voluntarily participate in clinical trial and the informed consent must be signed.
Exclusion criteria • Patients who are currently undergoing other anti-tumor therapies.
• Patients who were enrolled into any other clinical trial within 4 weeks of study entry.
• Any clinical laboratory findings give reasonable suspicion of a disease or condition that contraindicates
the use of any study medication or render the subject at high risk from treatment.
• Primary brain tumor or central nervous system metastatic tumor.
• Serious mental disorder.
• Serious dysgnosia or cognitive dysfunction.
• Other serious comorbidities.
• Alcohol or drug dependence.
• Previously allergic to drugs used in the study.
• Patients who are deemed unsuitable to participate in the study
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hematological toxicity and neuropathy. The incidence of
Grade 3-4 thrombocytopenia and anemia are higher in
Abraxane group than solvent-based paclitaxel arm, while
the incidence of neutropenia is higher in solvent-based
paclitaxel arm. Generally, the majority of hematological
toxicities in both arms are Grade 1-2 and manageable.
Grade 3-4 sensory neuropathy occurred more frequently
in solvent-based paclitaxel arm than Abraxane arm (12%
vs 3%) and the median time to improvement of Grade 3-4
neuropathy to Grade 1 is much less for Abraxane arm
than solvent-based paclitaxel arm (38 days vs 104 days).Thus Abraxane seems an optimal choice of third
generation chemotherapy agents to be combined with
platinum as the standard treatment due to its high
activity and favorable safety profile.
Moreover, retrospective subgroup analyses showed
that in squamous histology group, there were more
significant ORR benefit and OS improvement trend.
Squamous cell carcinoma consists approximately 30%
of all NSCLC but new treatment options are few. There is
huge unmet medical need to increase the prognosis
of this patient population. Abraxane has the active agent
of paclitaxel, which is an approved agent for treatment of
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property which increases the drug distribution and
concentration to a new level. Furthermore, studies have
showed that SPARC is an albumin-bound protein that is
rich in tumor matrix and may plays an important role in
absorbing Abraxane into the tumor site [12]. SPARC
may serve as a predictive or prognostic biomarker of
Abraxane-based therapy. Thus Abraxane has the potential
to be the optimal treatment choice in squamous carcinoma
of lung to achieve better response and survival.
This trial will be the first study to prospectively
compare Abraxane-based regimen with a currently
standard treatment for squamous histology patients. A
total of 120 patients will be randomized at a 1:1 ratio
to receive Abraxane 135 mg/m2, d1,8 plus carboplatin
AUC 5, d1, or gemcitabine 1,250 mg/m2 plus carboplatin
AUC 5, d1, both in a cycle of three weeks and up to six
cycles. The choice of Abraxane dosage and schedule is
based on previous researches and the phase III trial result.
Weekly Abraxane has been proved to have better efficacy
and safety than every three week schedule [13]. Compared
to 100 mg/m2 d1, 8, 15 in a four-week cycle in the
phase III trial, we implement a modified 135 mg/m2 , d1,
8 in a three-week cycle schedule to ensure a similar dose
intensity but more timely treatment break in order to
further reduce toxicity.
This study, together with findings from other phase
I/II/III studies of Abraxane in NSCLC, will provide
valuable insight to the role of Abraxane in the optimal
treatment choice for squamous carcinoma of lung.
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